Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
Rhea-AI Summary
Agios (Nasdaq: AGIO) will host a conference call and live webcast on Thursday, February 12, 2026 at 8:00 a.m. ET to report fourth quarter and full year 2025 financial results and business highlights. The live webcast will be available on the company’s Investors website under the "Events & Presentations" tab. A replay will be posted on the company website approximately two hours after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Several biotech peers show mixed moves, with multiple declines (e.g., DNLI -2.74%, APGE -10.43%) but scanner data does not flag a coordinated sector momentum move tied to this headline.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 16 | Q3 2025 call notice | Neutral | +0.3% | Scheduled Q3 2025 results call and webcast with replay details. |
| Jul 14 | Q2 2025 call notice | Neutral | +0.5% | Announced Q2 2025 financial results conference call and webcast timing. |
| Apr 17 | Q1 2025 call notice | Neutral | +1.9% | Set date and time for Q1 2025 financial results webcast and call. |
| Feb 06 | FY 2024 call notice | Neutral | +0.1% | Outlined upcoming Q4 and full year 2024 results call and webcast. |
| Oct 17 | Q3 2024 call notice | Neutral | +1.0% | Announced Q3 2024 results and business highlights webcast schedule. |
Similar conference-call earnings notices have historically prompted small, generally positive moves, with an average reaction of 0.77% across past events.
Over the past five quarters, Agios has regularly announced conference calls to discuss quarterly and annual results, all tagged as conferences,earnings. These events, from Oct 31, 2024 through Oct 30, 2025, consistently followed the same webcast-and-replay format and focused on financial results plus business updates. Market reactions around these notices were modestly positive, suggesting investors treat them as routine scheduling updates rather than new fundamental information.
Historical Comparison
In the past year, Agios issued 5 similar conferences/earnings call notices. Average move was about 0.77%, indicating these updates typically triggered only modest trading shifts.
Pattern shows consistent quarterly and annual earnings call scheduling across 2024–2025 with similar webcast and replay logistics.
Market Pulse Summary
This announcement sets the timing for Agios’s fourth quarter and full year 2025 results, with a webcast on February 12, 2026 at 8:00 a.m. ET and a replay available shortly after. Historically, similar conferences/earnings notices produced only modest average moves of about 0.77%, underscoring their routine nature. Investors may focus more on the forthcoming detailed financials and business updates rather than the scheduling news itself.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
morgan.sanford@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
eamonn.nolan@agios.com
FAQ
When will Agios (AGIO) report Q4 and full year 2025 results?
How can investors access the Agios (AGIO) live webcast on February 12, 2026?
Will there be a replay of the Agios (AGIO) February 12, 2026 webcast?
What topics will Agios (AGIO) cover on the February 12, 2026 call?
Is registration required to join the Agios (AGIO) webcast on February 12, 2026?
